Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
- Written by PR Newswire
 |
BRENTWOOD, Tenn., Aug. 27, 2024 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax") today announced the results of a Cardiovascular Health Outcomes Analysis (HOA). The results showed there is no evidence of excess cardiovascular risk and no statistically significant difference in major adverse cardiovascular events (MACE)...
